Company To Hold Conference Call and Webcast Tomorrow, Tuesday, August 11, 2015 at 9:00 AM EDT. STONY BROOK, NY. August 10, 2015

STONY BROOK, NY. August 10, 2015. Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced results of its third quarter of fiscal 2015.

Dr. James A. Hayward, President and Chief Executive Officer, stated: “We are very pleased to report our third consecutive quarter of record-setting revenues. Global recognition of our platforms continues to open new and varied business opportunities. Our fiscal third-quarter results demonstrate the significant strides we are making toward converting pilot projects to fully commercialized programs. During the quarter, we commenced delivery of SigNature® T DNA for the upcoming cotton-ginning season which begins next month. This DNA will be used to produce our PimaCott™ brand of SigNature-marked pima cotton, being taken up by a number of different brand-owners and retailers, and we believe for the first time ever, will secure the supply chain from field to consumer. Our work with two US government contracts continues towards commercialization of DNA marking on products from microcircuit manufacturing companies as well as in federal supply classes new to APDN.”

Financial Highlights for the Third Quarter:

• Revenues increased 170% for the third quarter of fiscal 2015 to a record $2.3 million, compared with $841 thousand reported in the third quarter of fiscal 2014, and a 49% increase from the $1.5 million reported in the second fiscal quarter ended March 31, 2015. This increase in revenues resulted primarily from sales in the textile industry for protecting cotton supply chains and revenue from two government contracts.
• Total operating expenses were $3.9 million, compared with $3.3 million in the prior year’s quarter, an increase of approximately $612 thousand or 18%.The increase is primarily attributable to an increase in non-cash stock-based compensation expense of $610 thousand offset by a decrease in legal fees.
• Net loss for the three months ended June 30, 2015 was $1.7 million, or $0.08 per share, compared with a net loss of $1.9 million, or $0.14 per share for the three months ended June 30, 2014 and a net loss of $1.9 million, or $0.11 per share for the three months ended March 31, 2015.
• Excluding non-cash expenses, Adjusted EBITDA for the three months ended June 30, 2015 was negative $478 thousand compared to a negative Adjusted EBITDA of $1.9 million (a decrease of 75%) for the same quarter last year and a negative Adjusted EBITDA of $1.2 million (a decrease of 61%) for our prior fiscal quarter. The improvement in adjusted EBITDA is primarily related to the increased revenues achieved with cash-based operating expenses remaining consistent for the three months ended June 30, 2015. See below for information regarding non-GAAP measures.

Recent Highlights:

• Signed Agreement with Louis Dreyfus Commodities. Using APDN’s SigNature® T DNA, cotton fibers will be tagged at the source or country of origin, allowing purity of content verification at all stages of the supply chain. Louis Dreyfus, one of the world’s largest cotton merchandisers, will provide secure logistics supply chain support for the tagging and authentication of cotton fibers.
• Launched Homegrown™ Source-Verified Upland Cotton from Grower to Consumer. Along with Divatex, Applied DNA Sciences will be tagging upland cotton fibers at the source, securing the supply chain of American grown cotton fiber, assuring that finished product is produced from cotton grown in the USA.
• Demands for APDN’s Home Asset Marking Program Increase. More municipalities are offering or recommending DNAnet® to their citizens, and we have trained over 30 regional police departments to recognize recovered assets that have been DNA-marked.

Dr. Hayward continued: “We are passing through a positive inflection in our business as pilot projects transition to commercial deployments and with market forces creating tailwinds. Adoption of our solutions by global supply chains creates revenue opportunity at each node when the products change hands. In our fiscal fourth quarter we will continue our focus on securing supply chains, expanding our role in government, and facilitating law enforcement and consumer protection.

• We will be working closely with our textiles partners to deliver a successful ginning season marking cotton. We expect additional brands and retailers to adopt SigNature T and our cotton genotypying program, known as fiberTyping®, to ensure the veracity of their label claims.
• We expect additional municipalities to support home asset marking with DNAnet, and we will continue to recruit the support of law enforcement.
• We will execute our federal contracts and partnerships with other commercial suppliers to the Department of Defense and other US government Agencies.
• The painful reality of recent cybersecurity attacks against the US and the fictional harbinger of cyberattacks to come painted by GhostFleet authors P.W. Singer and August Cole, point to the role of physical security in the prevention of cyberattacks. We believe there is no technology that offers the sensitivity, fidelity and forensic high-road to secure cyber supply chains and to deter cybercrime than DNA. We will continue to develop mechanisms in support of protecting semiconductors in high volume.

We believe our opportunities are substantial and that we have never been better positioned for growth.”

Financial Highlights for the First Nine Months:

• The Company recorded record nine-month revenues of over $5.0 million, an increase of 142% from the same period last fiscal year, and an 82% increase over full-year fiscal 2014 revenues, which was the Company’s prior annual record. The increase in revenues was primarily due to two government contracts,as well as revenues related to sales in the textile industry for protecting cotton supply chains.
• Operating expenses for the nine months ended June 30, 2015 increased by approximately $890 thousand or 8%. The increase is attributable to an increase in SG&A expenses of non-cash stock-based compensation expense of approximately $1.8 million, offset by decreases in legal and consulting expenses. This was also offset by a decrease in research and development expenses of approximately $124,000.
• Net loss for the nine months ended June 30, 2015 was $11.4 million or $0.63 per share, compared with a net loss of $11.0 million or $0.82 per share for the nine months ended June 30, 2014.
• Excluding non-cash expenses and interest, Adjusted EBITDA for the nine months ended June 30, 2015 was negative $3.4 million compared with an Adjusted EBITDA of negative $6.9 million (a decrease of approximately 50%) for the same period last year. See below for information regarding non-GAAP measures.

Fiscal Third-Quarter 2015 Conference Call Information
The Company will hold a conference call to discuss its third-quarter 2015 results tomorrow, August 11, 2015 at 9:00 AM EDT. To participate on the conference call, please follow the instructions below. A slide presentation that will accompany the call may be accessed using the following link: http://www.visualwebcaster.com/event.asp?id=102712

• Participant Toll Free: 888-503-8169
• Participant Toll: 719-325-2281
• Participant Passcode: 3567685

For those who cannot listen to the live broadcast, the presentation material and webcast replay of the call will be available at our investor relations website, https://adnasprod.wpengine.com/quarterly-results, by end of business on August 11, 2015.

While every attempt will be made to answer your questions, due to the large number of expected participants, not all questions may be answered on the call.

Information about Non-GAAP Financial Measures
Asused herein, “GAAP” refers to accounting principles generally accepted in the United States of America.

To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission.

Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared in presented in accordance with GAAP.

We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) change in fair value of warrant liability, (ii) the loss on conversion of promissory notes, (iii) stock-based compensation and (iv) other non-cash expenses.

The accompanying table below provides a reconciliation of the non-GAAP financial measure presented to the most directly comparable financial measure prepared in accordance with GAAP.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2015, May 11, 2015 and August 10, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

---

APPLIED DNA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2015 (unaudited)	June 30, 2015 (unaudited)
Assets
Current assets
Cash and cash equivalents	10,730,144	1,393,132
Accounts receivable, net of allowance of $30,228 and $9,634 at June 30, 2015 and September 30, 2014, respectively	2,077,756	834,818
Prepaid expenses and other current assets	209,831	135,365
Total current assets	13,017,731	2,363,315
Property, plant and equipment, net of accumulated depreciation of $743,914 at June 30, 2015 and $759,087 at September 30, 2014	526,816	576,128
Other assets:
Deposits	52,988	57,638
Deferred offering costs	0	181,104
Intangible assets, net of accumulated amortization and impairment of $325,555 and $256,208 at June 30, 2015 and September 30, 2014, respectively	525,902	327,872
Total Assets	14,123,437	3,506,057
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities, including related party accrued interest of $6,597 at September 30, 2014, respectively	1,418,615	1,494,759
Promissory notes payable, including $1,000,000 with a related party at September 30,2014	—	1,800,000
Deferred revenue	204,863	583,362
Total current liabilities	1,623,478	3,878,121
Warrant liability	—	1,096,412
Total liabilities	1,623,478	4,974,533
Commitments and contingencies
Stockholders’ Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014	—	—
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2015 and September 30, 2014	—	—
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2015 and September 30, 2014	—	—
Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized; 21,482,202 and 13,935,954 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively	21,483	13,937
Additional paid in capital	223,623,850	198,277,859
Accumulated deficit	(211,145,374)	(199,760,272)
Total stockholders’ equity (deficit)	12,499,959	(1,468,476)
Total Liabilities and Stockholders’ Equity (Deficit)	14,123,437	3,506,057

APPLIED DNA SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended June 30, 2015	Three Months Ended June 30, 2014	Nine Months Ended June 30, 2015	Nine Months Ended June 30, 2014
Revenues	$2,267,671	$841,197	$5,028,234	$2,075,698
Operating expenses:
Selling, general and administrative	3,508,455	2,948,452	11,078,405	10,093,631
Research and development	310,093	266,331	961,745	1,085,416
Depreciation and amortization	121,339	113,424	354,144	325,448
Total operating expenses	3,939,887	3,328,207	12,394,294	11,504,495
LOSS FROM OPERATIONS	(1,672,216)	(2,487,010)	(7,366,060)	(9,428,797)
Other income (expense):
Interest income (expense), net	5,052	111	(26,807)	784
Other (expense) income, net	(3,718)	52,299	(16,853)	130,186
Loss on conversion of promissory notes	–	–	(980,842)	–
Gain (loss) on change in fair value of warrant liability	–	515,543	(2,994,540)	(1,663,316)
Net loss before provision for income taxes	(1,670,882)	(1,919,057)	(11,385,102)	(10,961,143)
Provision for income taxes	–	–	–	–
NET LOSS	$(1,670,882)	$(1,919,057)	$(11,385,102)	$(10,961,143)
Net loss per share-basic and diluted	$(0.08)	$(0.14)	$(0.63)	$(0.82)
Weighted average shares outstanding-
Basic and diluted	21,444,335	13,569,262	18,075,506	13,400,540

APPLIED DNA SCIENCES, INC. CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA (Unaudited)

	Three Months Ended June 30, 2015	Three Months Ended June 30, 2014	Nine Months Ended June 30, 2015	Nine Months Ended June 30, 2014
Net Loss	$         (1,670,882)	$(1,919,057)	$(11,385,102)	$      (10,961,143)
Operating expenses:
Interest (income) expense, net	(5,052)	(111)	26,807	(784)
Depreciation and amortization	121,339	113,424	354,144	325,448
(Gain) loss on change in fair value of warrant liability	—	(515,543)	2,994,540	1,663,316
Stock based compensation expense	1,057,097	404,507	3,595,631	2,055,337
Loss on conversion of promissory notes	—	—	980,842	—
Bad debt expense	18,971	734	21,750	16,878
Total non-cash items	1,192,355	3,011	7,973,714	4,060,195
Consolidated Adjusted EBITDA (loss)	(478,527)	(1,916,046)	(3,411,388)	(6,900,948)

 

STONY BROOK, NY, June 16, 2015 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, supply chain and product authentication solutions, has signed an agreement with Louis Dreyfus Commodities, one of the world’s largest cotton merchandisers, to provide secure logistic supply chain support for the tagging and authentication of cotton fibers with SigNature® T DNA derived from botanical genomes.

Rodger Glaspey, Head of Western US operations for cotton at Louis Dreyfus Commodities, stated, “This unique partnership within the supply chain will help ensure that the consumer gets exactly what the label says: the finest cotton grown in the world today, 100% Pima Cotton grown in America.”

Using APDN’s patented SigNature T DNA technology, cotton fibers can be DNA-tagged at the source or country of origin, allowing purity of content verification at all stages of the supply chain. Bulk quantities of last year’s Pima harvest have already been processed using this method and are currently being verified throughout the supply chain, from the ginner, to the spinner and ultimately to the manufacturer. This year’s SigNature T tagging will begin at the start of the ginning season, at various locations in the United States.

Louis Dreyfus Commodities will collect the DNA-marking fees from its customers and pay them to APDN. It will also pay APDN to install their unique, patent-pending “DNA Application Systems” at each new gin, typically capable of DNA marking up to 50 million pounds of cotton per season. The DNA Application System measures the botanical DNA so that a constant level of DNA marking per pound of cotton is provided at extraordinarily low levels.

Dr. James A. Hayward, President and CEO of Applied DNA Sciences, commented: “We successfully installed SigNature T DNA Application systems here in the US, and will continue to implement them at other locations. The ‘traceability’ factor is the most compelling benefit that we offer because if it’s DNA-tagged we can tell you exactly where, when, by whom and how it was tagged.”

In tandem with DNA tagging, APDN will license its “On-Site™” DNA authentication technology to provide real time testing of raw cotton fiber and greige goods, yielding an end-to-end supply chain solution to guarantee quality and support product claims. The licenses will be offered to supply chain members at every point at which the DNA-marked cotton changes hands.

Facilitated by Louis Dreyfus Commodities, APDN and their recently announced partnership with Divatex Home Fashions, the SigNature T DNA tagged cotton fibers will provide customers with the ultimate end-to-end traceable solution.

Brand owners and retailers who comply with SigNature T marking and authentication for Pima cotton will be offered use of the “PimaCott™ Content Brand”, co-licensed by Divatex and APDN.“

Consumer interest in product traceability is growing rapidly. The ‘farm to table’ movement is a testament to the success that comes from being able to verify products at their source. Consumers of textiles and apparel support the philosophy because they are buying products that can help the local community, and know that the product is 100% pure. That is the power of PimaCott – it’s about paying it forward from the grower directly to the consumer. Everyone wins because, for the first time, there is a real solution to verify quality and authenticity,” said David Greenstein, CEO of Divatex.

The partners have already lined up their first customers and secured demand for over 20 million pounds of DNA-marked Pima cotton from multiple customers for the coming cotton-ginning season (September to January).

About Louis Dreyfus Commodities
Louis Dreyfus Commodities is a global merchandizer of commodities and processor of agricultural goods, operating a significant network of assets around the world. With annual revenues of $63.6 billion, the company helps to feed and clothe some 500 million people, originating, processing and transporting approximately 80 million tons of commodities annually. Today, Louis Dreyfus Commodities ranks as one of the largest cotton merchandising organizations in the world.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statement
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q, filed February 9, 2015 and May 11, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Wolcott-based Biopharmaceutical Company Announces Innovative Forensic Tagging Security Systems Made Possible Through Partnership with Long Island-based Biotech Firm

Wolcott, NY and Stony Brook, NY — June 15, 2015. Demonstrating its innovative and thoughtful commitment to the highest levels of security, Butler Evergreen formed an exclusive pre-application relationship with Stony Brook-based Applied DNA Sciences (NASDAQ: APDN) (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication and security solutions and services. Butler Evergreen has filed a comprehensive application to become a registered organization under New York State’s (“NYS”) Medical Marijuana program.“

When we mapped out our security protocols for production, distribution and dispensing, we wanted to use the absolute latest technology and innovation in the security field,” said Butler Evergreen CEO Scott Marshall. “As it happens, one of the leaders in this industry is another New York State-based biotechnology company, and we knew we wanted to work with them.”

Based on the partnership, Applied DNA Sciences will advise and consult Butler Evergreen in developing the most secure supply chain possible, with a particular focus on protecting products during transit and at dispensary locations if Butler Evergreen’s NYS application is approved.

Among other systems, Butler Evergreen intends to install Applied DNA Sciences’ SigNature® DNA in its transport boxes and armored vehicles. Similar to dye packs, this DNA tagging technology will discharge a liquid dye when a transport box is illegally accessed, tagging perpetrators and products with an event-specific, traceable SigNature DNA taggant.

Similarly, Butler Evergreen intends to install Applied DNA Sciences’ SmokeCloak® DNA System and Sentry Intruder Tagging System at dispensing locations. Should any security breach occur, intruders will again be tagged with a unique SigNature DNA mark. These incident-specific marks are traceable for 10 days on the subject’s skin and several months on the subject’s clothing and shoes. These systems will serve as a forensic tool that provides law enforcement with a means to identify offenders and any compromised products. The systems will also serve as powerful deterrent, with signage and labels letting possible offenders know that Butler Evergreen products are extremely secure.

Butler Evergreen also plans to use Applied DNA Sciences’ technology to create product packaging. This will enhance seed-to-sale security, enabling the company to identify a product as authentic through unique SigNature DNA marks embedded in labels and packages.

“Working with Butler Evergreen will help to add an unprecedented level of security to this application for the state’s medical marijuana program,” said Applied DNA Sciences CEO James Hayward. “Our company offers security systems with unique, botanical and ‘green’ DNA sequences to help preserve the quality and integrity of products. In seeking out Applied DNA Sciences, Butler Evergreen is showing the world that it is taking the security of its medical products as seriously as possible.”

Scott Marshall added, “Keeping our medical marijuana products safe and secure for our patients — and out of the wrong hands — is our top priority. That’s what our partnership with Applied DNA Sciences will help us accomplish.”

About Butler Evergreen
Butler Evergreen is focused on meeting patients’ needs with state-of-the-art production of marijuana-based biopharmaceutical products. At Butler Evergreen, we will use the latest advancements in controlled-environment agriculture, biomedical processing and secure delivery systems to help New Yorkers who suffer from cancer, epilepsy, MS, ALS, Parkinson disease and other illnesses live more fruitful lives. Everything we do is for the well-being of patients.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statement
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q, filed February 9, 2015 and May 11, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

STONY BROOK, NY, June 4, 2015 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, supply chain and product authentication solutions, with Divatex, a leading supplier of home textiles, today announced the launch of HomeGrown™ — Cotton Proudly Grown in the USA. HomeGrown cotton will be exclusively American grown upland cotton. These fibers will be tagged at source, and verified from grower to consumer through Applied DNA Sciences’ botanical DNA traceability technology.

“We sometimes forget that textiles are as much an agricultural product as an industrial one. I’m convinced that the domestic consumer will appreciate, that while ‘Made in the USA’ might not always be possible, ‘Grown in the USA’ most certainly is. In this unique way we are giving our customers a way to directly identify with the US growers, and support them,” stated David Greenstein, CEO, Divatex.

“Upland cotton, or what we refer to genetically as Gossypium hirsutum, is also the most widely planted species of cotton in the United States, accounting for at least 95% of all cotton production here. Our SigNature® T DNA tagging technology can be used to secure the supply chain of American grown cotton fiber, assuring that finished product is produced from cotton that has been proudly grown in the USA,” commented Dr. James Hayward, President and CEO, Applied DNA Sciences.

For more information about HomeGrown, please contact MeiLin Wan at meilin.wan@adnas.com.

About Applied DNA
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature^® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet^®, our anti-theft product, SigNature^® T, targeted toward textiles, and digitalDNA^®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences’ common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2015 and May 11, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Financial Results Driven by Revenue Enhancement and Reduced Expenses. Webcast To Be Held Today at 9:00 AM EDT.

STONY BROOK, NY. May 12, 2015. Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced results of its second quarter of fiscal 2015.“Our record quarterly revenues contributed to six-month revenues that are greater than any prior full fiscal year. This is an exciting achievement for our Company,” stated Beth Jantzen, Chief Financial Officer of Applied DNA Sciences.

Financial Highlights for the Second Quarter:

• Revenues increased 138% for the second quarter of fiscal 2015 to a record $1.5 million, compared with $637 thousand reported in the second quarter of fiscal 2014, and a 22% increase from $1.2 million reported in the first fiscal quarter ended December 31, 2014. This increase in revenues resulted primarily from an increase in revenues from government contracts.
• Total operating expenses were $3.4 million, compared with $3.8 million in the prior year’s quarter, a decrease of approximately $367 thousand or 10%. The decrease is primarily attributable to a decrease in legal fees, as well as lower selling, general and administrative expenses (“SG&A”) as a result of management’s cost-savings program.
• Net loss for the three months ended March 31, 2015 was $1.9 million, or $0.11 per share, compared with a net loss of $2.8 million, or $0.20 per share for the three months ended March 31, 2014 and a net loss of $7.8 million, or $0.51 per share for the three months ended December 31, 2014.
• Excluding non-cash expenses, Adjusted EBITDA for the three months ended March 31, 2015 would have been a negative $1.2 million compared to a negative Adjusted EBITDA of $2.6 million for the same quarter last year and a negative Adjusted EBITDA of $1.7 million for our prior fiscal quarter. The improvement in adjusted EBITDA is primarily related to the increased revenues and decreased operating expenses for the three months ended March 31, 2015, as described above. See below for information regarding non-GAAP measures.

Financial Highlights for the First Six Months:

• The Company recorded record six-month revenues of almost $2.8 million, an increase of 124% from the same period last fiscal year, beating full-year fiscal 2014 revenues, which was the Company’s prior annual record. The increase in revenues was primarily due to two government contracts, revenues related to textile sales for protecting cotton supply chains, and an increase in sales of DNAnet kits.
• Operating expenses for the six months ended March 31, 2015 increased by approximately $280 thousand or 3%. The increase is attributable to an increase in SG&A expenses of approximately $427 thousand, including an increase in stock based compensation expense of approximately $1.2 million, offset by decreases in legal and consulting expenses. The increase in operating expenses was also offset by a decrease in research and development expenses of approximately $167 thousand.
• Net loss for the six months ended March 31, 2015 was $9.7 million or $0.59 per share, compared with a net loss of $9.0, million or $0.68 per share for the six months ended March 31, 2014.
• Excluding non-cash expenses and interest Adjusted EBITDA for the six months ended March 31, 2015 would have been a negative $2.9 million compared with an Adjusted EBITDA of negative $5.0 million for the same period last year. See below for information regarding nonGAAP measures.

Dr. James A. Hayward, President and Chief Executive Officer, stated: “We are very pleased with the increase in revenues, the continued recognition of our technology and products on a global basis, and the many business opportunities that have opened up to us as we increase our customer base. In addition to top-line improvements, we reduced our expenses and successfully completed a public offering right after the quarter ended that brought us new investors and capital to support our commitment to turning a profit. We expect continued growth in our government revenue for the year, the recruitment of new brands and retailers in our textiles business, and a strong response to our Home Asset Marking initiatives.”

Recent Highlights: 

• Closed on $12.0 million public offering. On April 1, 2015, the Company closed on an underwritten public offering for gross proceeds of $12 million. On April 30, the Company closed on the over allotment option for additional gross proceeds of $264 thousand.
• Introduction of DNAnet® Home Asset Marking. In a recent media event with local politicians, APDN announced the introduction of its DNAnet kits for home asset marking in Huntington Station, NY. Multiple US and EU municipalities have expressed interest, and insurance companies have begun direct marketing of DNAnet to their insured.
• Entered into License Agreement with Divatex. Using Applied DNA Sciences’ patented SigNature® T DNA technology, U.S.-grown cotton fibers will be DNA-tagged at the ginner, offering the ability to verify the origin of the cotton throughout the supply chain.
• Launched On-Site™ Authentication. SigNature DNA and fragmented DNA segments are forensically detectable in a field-deployable format. Licensees will be supplied devices in exchange for annual testing commitments. On-Site testing accelerates DNA-based quality release and assures authenticity at every node in which a product changes hands.
• Compliance with FDA Guideline. Received a legal opinion stating that SigNature DNA is considered to be suitable for inclusion in prescription drugs as a PCID (“Physico-Chemical Identifier”) to help authenticate originality and exclude counterfeit drugs from the supply chain.
• Launched DNA Beacon™. Based on a panel of novel, fluorescent-encrypted security elements, this patent pending technology is designed to identify SigNature DNA marked products throughout an entire supply chain. Identification in the field is easily conducted. Beacon technology can survive flame temperatures in excess of 1,000°C, making it well suited to prevent crimes such as copper theft.

Dr. Hayward concluded: “We continue to focus on new business opportunities, operational improvements and efficiencies as we expand our customer base and penetration of key industry verticals.”

Webcast Information:
The Company will be hosting a webinar today, May 12, 2015 at 9:00 AM EDT. To participate in the webinar, please follow the instructions below:

Reserve your webinar seat now at: https://attendee.gotowebinar.com/register/935241658046078977

Please email questions prior to the call to investor@adnas.com. While every attempt will be made to answer your questions, due to the large number of expected participants, not all questions may be answered on the call. For those of you unable to participate, the webinar will be posted by end of business on May 12, 2015, and available under the “Investors” tab of the Company’s website.

Information about Non-GAAP Financial Measures
As used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared in presented in accordance with GAAP.We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this nonGAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

“EBITDA” – is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

“Adjusted EBITDA” – is defined as EBITDA adjusted to exclude (i) change in fair value of warrant liability, (ii) the loss on conversion of promissory notes, (iii) stock-based compensation and (iv) other non-cash expenses.

The accompanying table below provides a reconciliation of the non-GAAP financial measure presented to the most directly comparable financial measure prepared in accordance with GAAP.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our antitheft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2015 and May 11, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Applied DNA Sciences, Inc. Condensed Consolidated Balance Sheets

	March 31, 2015 (unaudited)	September 30, 2014
Assets
Current Assets
Cash and cash equivalents	984,050	1,393,132
Accounts receivable, net of allowance of $11,257 and $9,634 at March 31, 2015 and September 30, 2014, respectively	1,160,304	834,818
Prepaid expenses and other current assets	155,593	135,365
Total current assets	2,299,947	2,363,315
Property, plant and equipment, net of accumulated depreciation of $645,855 at March 31, 2015 and $759,087 at September 30, 2014	587,600	576,128
Other assets:
Deposits	61,988	57,638
Deferred offering costs	287,831	181,104
Intangible assets, net of accumulated amortization and impairment of $302,610 and $256,208 at March 31, 2015 and September 30, 2014, respectively	389,470	327,872
Total Assets	3,626,836	3,506,057
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities, including related party accrued interest of $– and $6,597 at March 31, 2015 and September 30, 2014, respectively	1,443,665	1,494,759
Promissory notes payable, including $1,000,000 with a related party	—	1,800,000
Deferred revenue	227,810	583,362
Total current liabilities	1,671,475	3,878,121
Warrant liability	—	1,096,412
Total liabilities	1,671,475	4,974,533
Commitments and contingencies (Note I)
Stockholders’ Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2015 and September 30, 2014	—	—
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of March 31, 2015 and September 30, 2014	—	—
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of March 31, 2015 and September 30, 2014	—	—
Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized; 17,369,202 and 13,935,954 shares issued and outstanding as of March 31, 2015 and September 30, 2014, respectively	17,370	13,937
Additional paid in capital	211,412,483	198,277,859
Accumulated deficit	(209,474,492)	(199,760,272)
Total stockholders’ equity (deficit)	1,955,361	(1,468,476)
Total Liabilities and Stockholders’ Equity (Deficit)	3,626,836	3,506,057

Applied DNA Sciences, Inc. Condensed Consolidated Statements Of Operations (Unaudited)

	Three Months Ended March 31, 2015	Three Months Ended March 31, 2014	Six Months Ended March 31, 2015	Six Months Ended March 31, 2014
Revenues	$1,518,761	$637,146	$2,760,563	$1,234,500
Operating expenses:
Selling, general and administrative	2,901,207	3,297,739	7,569,950	7,143,317
Research and development	373,380	359,782	651,652	819,086
Depreciation and amortization	123,079	106,810	232,805	212,025
Total operating expenses	3,397,666	3,764,331	8,454,407	8,174,428
LOSS FROM OPERATIONS	(1,878,905)	(3,127,185)	(5,693,844)	(6,939,928)
Other income (expense):
Interest income (expense), net	16	239	(31,859)	673
Other (expense) income, net	(6,693)	(79,389)	(13,135)	76,028
Loss on conversion of promissory notes	–	–	(980,842)	–
Gain (loss) on change in fair value of warrant liability	–	455,899	(2,994,540)	(2,178,859)
Net loss before provision for income taxes	(1,885,582)	(2,750,436)	(9,714,220)	(9,042,086)
Provision for income taxes	–	–	–	–
NET LOSS	$ (1,885,582)	$ (2,750,436)	$ (9,714,220)	$ (9,042,086)
Net loss per share-basic and diluted	$ (0.11)	$ (0.20)	$ (0.59)	$ (0.68)
Weighted average shares outstanding- Basic and diluted	17,362,573	13,470,806	16,404,299	13,316,179

Applied DNA Sciences, Inc. Calculation And Reconciliation Of Adjusted EBITDA (Unaudited)

	Three Months Ended March 31, 2015	Three Months Ended March 31, 2014	Six Months Ended March 31, 2015	Six Months Ended March 31, 2014
Net Loss	$(1,885,582)	$(2,750,436)	$(9,714,220)	$(9,042,086)
Operating expenses:
Interest (income) expense, net	(16)	(239)	31,859	(673)
Depreciation and amortization	123,079	106,810	232,805	212,025
(Gain) loss on change in fair value of warrant liability	—	(455,899)	2,994,540	2,178,859
Stock based compensation expense	539,996	547,784	2,538,519	1,650,831
Loss on conversion of promissory notes	—	—	980,842	—
Bad debt expense	—	1,144	2,779	16,144
Total non-cash items	663,059	199,600	6,781,344	4,057,186
Consolidated Adjusted EBITDA (loss)	$(1,222,523)	$(2,550,836)	$(2,932,876)	$(4,984,900)

This Patent Is a Continuation of Previously Granted Patent US. 8,372,648 With Broader Claims (9,005,985 on April 14, 2015)

STONY BROOK, NY. April 21, 2015 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology supply chain and product authentication solutions, announced that the US Patent and Trademark Office issued the “Optical Reporter Compositions” patent # 9,005,985 on April 14, 2015, which will strengthen our position in the field of covert markers.

This patent broadens the claims of previously granted US Patent No. 8,372,648, and allows the patent to cover a broader range of optical marker formulation composition.

• This patent allows more flexibility in optical marker formulation and expands the range of possible optical markers that we can produce.
• It is now possible to generate optical markers of various properties and, in conjunction with covalently linked DNA, forms a range of new markers with both instant read and forensic qualities.

Dr. Benjamin Liang, Chief Scientific Officer, APDN, stated: “This patent demonstrates our continuous effort in developing new line of field-readable forensic markers. When coupled with our in-field multimode readers, on-site authentication has become a reality.”

Dr. James Hayward, President and CEO of Applied DNA Sciences, stated: “Whether used in anti-counterfeit packaging, law enforcement or the protection of home assets, these markers enable the on-site recognition of complex spectra for our DNA-associated covert marks. We are steadily adding to our authentication toolbox.”

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature^® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet^® , our anti-theft product, SigNature^® T, targeted toward textiles, and digitalDNA^®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly report on Form 10-Q filed on February 9, 2015 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

STONY BROOK, NY, April 3, 2015. Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced that its Annual Meeting of Stockholders will be held on June 16, 2015 at 10:00 AM EDT at the CEWIT in Stony Brook, New York.  APDN also announced that its Board of Directors has set the close of business on April 17, 2015 as the record date for determining who may vote at the meeting. All stockholders as of the record date are invited to attend the Annual Meeting where Dr. James Hayward, President and CEO, and Ms. Beth Jantzen, CFO, will discuss the latest accomplishments of the company.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature^® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet^®, our anti-theft product, SigNature^® T, targeted toward textiles, and digitalDNA^®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly report on Form 10-Q filed on February 9, 2015 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

STONY BROOK, NY, March 27, 2015 – Applied DNA Sciences, Inc. (NASDAQ: Common Stock-APDN, Warrants-APDNW) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, supply chain and product authentication solutions, announced that it has priced its previously announced underwritten public offering of 3,820,000 shares of its common stock and warrants to purchase up to an aggregate of 1,528,000 shares of common stock, at a combined public offering price of $3.00. The warrants have an exercise price of $3.50 per share, expire on November 20, 2019 and will trade under the symbol APDNW.

The gross proceeds to the Company from this offering are estimated to be approximately $11.46 million before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriters a 45-day option to purchase an aggregate of up to 573,000 additional shares of common stock and/or warrants to purchase up to 229,200 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about April 1, 2015, subject to customary closing conditions.

The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, business development and research and development and acquisitions of new technologies or businesses.

Maxim Group LLC is acting as the sole book runner for the offering with The Benchmark Company acting as Co-Manager.

The securities described above are being offered by Applied DNA Sciences pursuant to a “shelf” registration statement on Form S-3 (File No. 333-202432) filed with the Securities and Exchange Commission, or the SEC, which was declared effective by the SEC on March 10, 2015. Copies of the final prospectus supplement to be dated March 27, 2015 and accompanying base prospectus relating to the offering will be filed with the SEC and, when available, can be obtained by contacting Maxim Group LLC by telephone at 212-895-3475 or by e-mail at syndicate@maximgrp.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Additional information can be found in the Company’s filings with the SEC available at www.sec.gov and on the Company’s website at www.adnas.com.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statement
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015 and our subsequent quarterly report on Form 10-Q filed on February 9, 2015 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

STONY BROOK, NY. March 26, 2015. Applied DNA Sciences, Inc. (NASDAQ: APDN) (NASDAQ: APDNW) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, supply chain and product authentication solutions, announced that it intends to offer shares of common stock and warrants to purchase common stock in an underwritten public offering. Maxim Group LLC will serve as the sole book runner for the offering with The Benchmark Company acting as Co-Manager. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, business development and research and development and acquisitions of new technologies or businesses.

A preliminary prospectus supplement will be filed with the Securities and Exchange Commission and will be available at the SEC’s website atwww.sec.gov. Copies of the preliminary prospectus supplement may be obtained by contacting Maxim Group LLC by telephone at 212.895.3745 or by e-mail at syndicate@maximgrp.com.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on March 2, 2015.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statement
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015 and our subsequent quarterly report on Form 10-Q filed on February 9, 2015 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.